timothy sykes logo
AZN Jumps As AstraZeneca PLC Delivers Big Oncology Wins And Earnings Beat Thumbnail
G Google News

AZN Jumps As AstraZeneca PLC Delivers Big Oncology Wins And Earnings Beat

JACK KELLOGG•UPDATED NOV. 1, 2026, 10:07 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

AstraZeneca PLC stocks have been trading up by 6.85 percent on optimism driven by strong late-stage drug trial results.

What Traders Need To Know

  • Phase III DeLLphi-305 data showed IMFINZI plus Amgen’s tarlatamab cut the risk of death by 58% versus IMFINZI alone in extensive-stage small cell lung cancer, with median survival reaching a record 21.1 months.
  • The Phase III VOLGA trial found perioperative IMFINZI plus enfortumab vedotin significantly improved survival outcomes in muscle-invasive bladder cancer and secured FDA Priority Review.
  • AstraZeneca’s CLDN18.2-targeting ADC Sone-Ve cut the risk of death by 42–53% versus standard therapies in advanced gastric/GEJ cancers, potentially covering up to about 60% of these patients.
  • The Phase III SAFFRON trial showed TAGRISSO plus savolitinib outperformed chemotherapy in MET-driven, EGFR-mutated NSCLC after TAGRISSO progression, and a US NDA is already filed.
  • Q3 results topped expectations with core EPS at $2.79 and revenue at $16.21B, supported by 7% revenue growth, 14% EPS growth, and a wave of late-stage oncology successes.

Candlestick Chart

Weekly Update Oct 26 – Oct 30, 2026: On Sunday, November 01, 2026 AstraZeneca PLC stock [NYSE: AZN] is trending up by 6.85%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

AstraZeneca holds a top-tier global pharma position with £58.7B in revenue and robust high-value mix, as evidenced by an 81.9% gross margin and EBIT margin above 23%. Revenue CAGR of ~11% over three years and >30% over five underscores durable growth, while ROE near 22% and ROIC ~15–16% place returns well above the healthcare large-cap median. Leverage is moderate (total debt/equity 0.64; interest cover 11.9x), though sub-1.0 liquidity ratios warrant monitoring. Valuation at ~24x earnings and 4.1x sales embeds strong growth but remains reasonable versus premium oncology peers.

Technically, the weekly tape shows a clear short-term uptrend: closes have climbed from ~171 to ~186 over five sessions, with successive higher highs and higher lows. The sharp move from 174.99 to 186.35 suggests a breakout leg, likely supported by elevated volume around the Q3 beat and oncology data. Dominant trend is bullish above the 174–176 breakout zone, which now serves as key support. A concrete actionable level: buy pullbacks toward 178–180 with a stop below 174 and initial profit-taking into the 192–195 area.

Fundamentally and from news flow, AstraZeneca is outperforming sector benchmarks: multiple positive Phase III readouts (DeLLphi-305, VOLGA, SAFFRON, CLARITY-Gastric01) and Enhertu/ZEGFROVY approvals extend leadership in IO, ADCs, and targeted oncology versus large-cap pharma peers. Q3 revenue and EPS beats, plus reaffirmed double-digit EPS growth guidance, support a premium multiple. Versus global pharma P/E averages in the high-teens, AZN’s pipeline justifies upside; I see a 12-month fair value zone of 195–205, with strong support near 174 and resistance around 205.

More Breaking News

Quick Financial Overview

AstraZeneca PLC (AZN) is pairing strong clinical news flow with solid fundamentals. Q3 revenue of $16.21B and 7% year-on-year growth show that pipeline wins are feeding into the top line. Core EPS grew 14% to $2.79, which, together with a profit margin above 17% and EBIT margin of 23.3%, signals healthy operating leverage. Gross margin near 81.9% underlines the high-value nature of AZN’s oncology and specialty portfolio.

On the balance sheet, a total debt-to-equity ratio of 0.64 and interest coverage of 11.9 suggest manageable leverage, but a current ratio of 0.9 and quick ratio of 0.6 mean liquidity is tight rather than flush. Return on equity above 21% and ROIC around the mid-teens point to efficient capital use. Valuation is not cheap: a P/E near 24 and price-to-sales about 4.1 reflect the market already pricing in a premium growth story.

Price action confirms that traders are buying the oncology narrative. AZN’s weekly chart shows a sharp move from the low $170s to above $186, with the biggest jump coming after the Q3 beat, consistent with headlines of a 6–7% surge on the day. Intraday, the 5‑minute candle around the earnings move shows a spike from roughly $183.59 to a $188.39 high before settling near $186.65, classic momentum behavior on strong news. For now, the $185–$187 zone looks like the new battleground where short-term bulls and profit-takers will test each other.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”